Ardena, a CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces that its new GLP bioanalytical laboratory in Somerset, New Jersey, is now operational and supporting client studies.
Arterex has announced the expansion of its facility in Mansfield, Massachusetts, USA, which specialises in the development and manufacturing of FDA Class 2 and Class 3 electromechanical devices (EMDs) and implantable devices for OEMS.
Samsung Biologics has announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.
Bracco Imaging announced an upgrade of its manufacturing site in Geneva to support clinical-grade GMP manufacturing of its cell therapy-enabling microbubble technology, building on its previously announced Investments in the site since 2019.
At this year’s DCAT Week, Olon is outlining its 2026 development plan, aimed at expanding capabilities across its global network, including the United States, India, Italy, and France, through targeted investments and infrastructure upgrades.
Wilmington PharmaTech has announced a $50 million expansion of its Delaware campus to more than double its current API reactor capacity, supporting growing demand for high-quality, US-based manufacturing.
Clariant is expanding its Clear Lake site to include excipient GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients, aiming to improve their availability and reliability for North American customers.
Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus, with further capacity expansions planned as client demand increases.
FUJIFILM Biotechnologies, a contract development and manufacturing organisation (CDMO) for biologics, vaccines, and advanced therapies, celebrated the grand opening of its expanded site in Teesside, UK on 11th February.
